A phase 2 multicenter, randomized, placebo-controlled, parallel group dose-ranging study to evaluate the safety and efficacy of topical NEOSH101 in the treatment of androgenetic alopecia in men
Latest Information Update: 21 Jul 2011
At a glance
- Drugs NEOSH 101 (Primary)
- Indications Male pattern baldness
- Focus Therapeutic Use
- Sponsors Neosil
- 10 Jan 2008 Status changed from recruiting to in progress.
- 06 Jul 2007 New trial record.